浏览全部资源
扫码关注微信
1.西华师范大学 西南野生动植物资源保护教育部重点实验室,四川 南充 637009
2.成都中医药大学 公共卫生学院,成都 610075
Published:20 July 2022,
Published Online:19 April 2022,
Received:10 February 2022,
扫 描 看 全 文
张健萍,裴容,汪海燕等.川芎嗪单独及联合西药抗肿瘤作用研究进展[J].中国实验方剂学杂志,2022,28(14):235-241.
ZHANG Jianping,PEI Rong,WANG Haiyan,et al.Anti-tumor Effect of Ligustrazine Alone and in Combination with Western Medicine: A Review[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):235-241.
张健萍,裴容,汪海燕等.川芎嗪单独及联合西药抗肿瘤作用研究进展[J].中国实验方剂学杂志,2022,28(14):235-241. DOI: 10.13422/j.cnki.syfjx.20221326.
ZHANG Jianping,PEI Rong,WANG Haiyan,et al.Anti-tumor Effect of Ligustrazine Alone and in Combination with Western Medicine: A Review[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):235-241. DOI: 10.13422/j.cnki.syfjx.20221326.
随着环境问题和人口老龄化越来越严重,全世界的癌症数量急剧增加。对于现代医学水平来说,癌症是无法根治的恶性疾病,具有转移率高、细胞增殖和侵袭能力强等特点。目前临床抗癌治疗主要包括化疗和放疗,但多数化疗药物可引发严重的不良反应。因此,高安全性的传统中药目前被广泛应用于抗癌治疗中,具有抑制癌细胞增殖、提高生存质量、延长寿命等作用。川芎嗪是由川芎中分离得到的一种生物碱,具有抗纤维化,抗氧化和抗肿瘤等药理作用。近年来,川芎嗪作为川芎生物碱的指标活性物质,其药理作用逐渐成为临床医学研究的热点之一,且抗肿瘤作用更受研究者关注。该文主要从川芎嗪诱导肿瘤细胞凋亡和自噬、抑制细胞增殖和迁移、逆转癌细胞的多重耐药性、抑制新生血管的形成等4个方面探讨了其抗癌作用,且在肝癌、胃癌、肺癌、直肠癌、膀胱癌、乳腺癌、卵巢癌等多种恶性肿瘤中均观察到抗肿瘤功效;此外川芎嗪还可联合顺铂、紫杉醇、鬼臼毒素、查尔酮、姜黄素等药物发挥抗肿瘤作用。为此,该研究基于川芎嗪抗肿瘤作用机制途径进行文献综述,以期为临床恶性肿瘤的治疗提供参考。
With serious environmental problems and the aging of population, the incidence of cancers worldwide has increased dramatically. For modern medicine, cancer is an incurable malignant disease with a high metastasis rate and strong cell proliferation and invasion ability. At present, clinical anti-cancer therapies mainly include chemotherapy and radiotherapy, but most chemotherapy drugs can cause serious side effects. Therefore, Chinese medicine with high safety has been widely used in anti-cancer treatment, which can inhibit the proliferation of cancer cells, improve the quality of life, and prolong life. Ligustrazine is a pyrazine alkaloid isolated and purified from Chuanxiong Rhizoma, which has pharmacological effects, such as anti-fibrosis, anti-oxidation, and anti-tumor. In recent years, ligustrazine, as an index active component of Chuanxiong Rhizoma alkaloids, has gradually become one of the hot spots in clinical medical research due to its pharmacological actions, and its anti-tumor effect has attracted more attention from researchers. The present study mainly investigated the anti-cancer effect of ligustrazine from the induction of tumor cell apoptosis and autophagy, inhibition of cell proliferation and migration, reversal of multidrug resistance of cancer cells, and inhibition of angiogenesis, and the anti-tumor efficacy was observed in various malignancies such as gastric cancer, lung cancer, rectal cancer, bladder cancer, breast cancer, and ovarian cancer. In addition, ligustrazine can be combined with cisplatin, paclitaxel, podophyllotoxin, chalcone, curcumin, and other drugs to exert an anti-tumor effect. This study conducted a literature review based on the anti-tumor mechanism of ligustrazine to provide a reference for the treatment of clinical malignancies.
川芎嗪抗肿瘤机制联合研究进展
ligustrazineanti-tumormechanismcombinationresearch progress
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021 ,71(1):7-33.
QIU H, CAO S, XU R. Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond),2021 ,41(10):1037-1048.
国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2020:1088.
YAN S, YUE Y Z, ZONG Y, et al. Tetramethylpyrazine improves postoperative tissue adhesion: A drug repurposing[J]. Chin J Integr Med,2019,25(7):554-560.
CHEN L, LIU T, WANG Q, et al. Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo[J]. BMC Complement Altern Med,2017,17 (1):233.
马瑞.川芎嗪对 H22 肝癌小鼠血管生成及KLF4/VEGF/ADAMTS1 的通路影响[D].洛阳:河南科技大学,2020.
ZOU Y, ZHAO D, YAN C, et al. Novel ligustrazine-based analogs of piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo[J]. J Med Chem, 2018, 61(5):1821-1832.
CHEN J, WANG W, WANG H, et al. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis[J]. Drug Discov Ther,2014,8(1):33-41.
KOTAKE Y, KITAGAWA K, OHHATA T, et al. Long non-coding RNA, PANDA, contributes to the stabilization of p53 tumor suppressor protein[J]. Anticancer Res ,2016,36(4):1605-1611.
BIAN Y, YANG L, SHENG W, et al. Ligustrazine induces the colorectal cancer cells apoptosis via p53-dependent mitochondrial pathway and cell cycle arrest at the G0/G1 phase[J].Ann Palliat Med, 2021,10(2):1578-1588.
CAO J, MIAO Q, MIAO S, et al. Tetramethylpyrazine exerts antitumor effects by inducing apoptosis and autophagy in hepatocellular carcinoma[J]. Int Immunopharmacol,2015,28(3):212-220.
SHINTANI Y, KAPOOR A, KANEKO M, et al. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons[J]. Proc Natl Acad Sci USA,2013,110(13): 5109-5114.
易波. ROS/AMPK介导的凋亡通路在川芎嗪抗胃癌作用中的机制研究[D].南昌:南昌大学第二附属医院,2013:1-62.
RISSO G, BLAUSTEIN M, POZZI B, et al. Akt/PKB: One kinase, many modifications[J]. Biochem J,2015,468(2):203-214.
SHEN J, ZENG L, PAN L, et al. Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3[J]. Oncol Lett,2018,15(4):4557-4563.
XUE F, LI Q R, XU Y H, et al. MicroRNA-139-3p inhibits the growth and metastasis of ovarian cancer by inhibiting ELAVL1[J]. Onco Targets Ther,2019,12:8935-8945.
XU D, CHI G, ZHAO C, et al. Ligustrazine inhibits growth, migration and invasion of medulloblastoma Daoy cells by up-regulation of miR-211[J].Cell Physiol Biochem,2018,49(5):2012-2021.
ZHANG H, DING S, XIA L. Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211[J]. Biosci Rep,2021,41(1):1-10.
REUTER S, GUPTA S C, CHATURVEDI M M, et al. Oxidative stress, inflammation, and cancer: How are they linked[J]. Free RadicBiol Med,2010,49(11):1603-1616.
GIL M,YUN K K,KIM K E,et al.Cellular prion protein regulates invasion and migration of breast cancer cells through MMP-9 activity[J]. Biochem Biophys Res Commun,2016,470 (1) : 213 -219.
庞皓玥,胡凯文,孙满强,等.川芎嗪通过减少肺癌A549细胞内活性氧的生成抑制细胞增殖及侵袭[J].现代肿瘤医学,2021,29(21):3695-3699.
郑春燕.COX-2介导川芎嗪抑制肺癌A549细胞侵袭转移的作用研究[D].青岛:山东大学医学院,2012.
陈杨林. AMPKα及其相关通路在川芎嗪抗胃癌细胞侵袭和迁移作用中的机制研究[D].南昌:南昌大学附属肿瘤医院,2021.
CARMELIET P, JAIN R K. Angiogenesis in cancer and other diseases[J]. Nature,2000,407(6801):249-257.
WANG S, CAI R, MA J, et al. The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells[J]. Phytomedicine,2015,22(11):1017-1026.
LIU D, WANG J, KINZEL B, et al. Dosage-dependent requirement of BMP type Ⅱ receptor for maintenance of vascular integrity[J]. Blood, 2007,110(5): 1502-1510.
BEETS K, HUYLEBROECK D, MOYA I M, et al. Robustness in angiogenesis: Notch and BMP shaping waves[J]. Trends Genet , 2013,29(3): 140-149.
VALDIMARSDOTTIR G, GOUMANS M J, ROSENDAHL A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells[J]. Circulation , 2002,106(17): 2263-2270.
FONG S, DEBS R J, DESPREZ P Y. Id genes and proteins as promising targets in cancer therapy[J]. Trends Mol Med, 2004,10(8): 387-392.
JIA Y, WANG Z, ZANG A, et al. Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling[J]. Int J Oncol,2016,48(5):2079-2086.
ZHU Z, WITTE L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor[J].Invest New Drugs,1999,17(3):195-212.
赵利枝,杨日芳,汪海.内皮细胞与血管形成[J].中国药理学通报,2002,18(4):361-364.
刘志良,崔伦伯.川芎嗪对小鼠小细胞肺癌血管生长和VEGF表达的抑制[J].辽宁医学院学报,2009,30(1):13-16.
KELLNER U, SEHESTED M, JENSEN P B, et al. Culprit and victim-DNA topoisomerase ii[J]. Lancet Oncol,2002,3(4): 235-243.
WANG S, LEI T, ZHANG M. The reversal effect and its mechanisms of tetramethylpyrazine on multidrug resistance in human bladder cancer[J]. PLoS One,2016,11(7):1-19.
ZHOU C, SHEN P, CHENG Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells[J]. Biochim Biophys Acta,2007,1770(7):1011-1020.
ZHANG Y, LIU X, ZUO T, et al. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein[J]. Med Oncol, 2012,29(2):534-538.
PARDAENS R , DIRIX L , DUMEZ H , et al. Phase Ⅰ/Ⅱ pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer[J]. Clin Breast Cancer, 2007,7(11): 861-866.
HOLOHAN C, VAN SCHAEYBROECK S, LONGLEY D B, et al. Cancer drug resistance: An evolving paradigm[J]. Nat Rev Cancer, 2013,13(10): 714-726.
CHUA P J, LIM J P, GUO T T, et al. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cas-sette transporters in the chemoresistance of gastric cancer cells[J]. Int J Oncol, 2018,53(6): 2579-2589.
SUN W L, WANG L, LUO J, et al. Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12[J]. Cancer Sci, 2018,109(10): 3129-3138.
LIU Y L, YAN Z X, XIA Y, et al. Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression[J]. Am J Cancer Res,2020,10(3):939-952.
高传柱,王天帅,陈佳,等. 铂类抗肿瘤药物作用机制研究进展[J]. 昆明理工大学学报:自然科学版, 2014, 39(4):83-92.
TRAINI S, PICCOLO E, TINARI N, et al. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody[J]. Mol Cancer Ther, 2014, 13(4):916-925.
朱亚芳.川芎嗪联合顺铂对小鼠Lewis肺癌生长及90k、Arresten、VEGF的影响[D].张家口:河北北方学院附属第一医院,2016.
LUQUE A, CARPIZO D R, IRUELA-ARISPE M L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165[J]. J Biol Chem,2003,278(26): 23656-23665.
TANG J H, ZHANG H M, ZHANG Z H, et al. Effect of tetramethylpyrazine combined with cisplatin on VEGF , KLF4 and ADAMTS1 in Lewis lung cancer mice[J]. Asian Pac J Trop Med,2017,10(8):813-818.
WANG X, CHENG L, XIE H J, et al. Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer[J]. Artif Cells Nanomed Biotechnol, 2018,46(sup2):1154-1169.
FU N, LI H, SUN J, et al. Aqueous extract enhances the mobilization of endothelial progenitor cells and up-regulates the expression of VEGF, eNOS, NO, and MMP-9 in acute myocardial is chemicrats[J]. Front Physiol, 2018,doi: 10.3389/fphys.2017.01132http://dx.doi.org/10.3389/fphys.2017.01132.
LU S, ZHANG Z, CHEN M, et al. Silibinin inhibits the migration and invasion of human gastric cancer SGC7901 cells by downregulating MMP-2 and MMP-9 expression via the p38 MAPK signaling pathway[J]. Oncol Lett, 2017,14(6):7577-7582.
TAO M Z, GAO X, ZHOU T J, et al. Effects of TGF-β1 on the proliferation and apoptosis of human cervical cancer hela cells in vitro[J]. Cell Bioch Bioph,2015, doi: 10.1007/s12013-015-0673-xhttp://dx.doi.org/10.1007/s12013-015-0673-x.
RÖTZER V, HARTLIEB E, VIELMUTH F, et al. E-cadherin and Src associ-ate with extradesmosomal Dsg3 and modulate desmosome assembly and adhesion[J]. Cell Mol Life Sci,2015,72(24):4885-4897.
XIE H J, ZHAO J, ZHUO M A D, et al. Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer[J].Artif Cells Nanomed Biotechnol,2019,47(1):3465-3477.
ZOU L, LIU X, LI J, et al. Tetramethylpyrazine enhances the antitumor effect of paclitaxel by inhibiting angiogenesis and inducing apoptosis[J]. Front Pharmacol,2019,707(10):1-12.
ZOU L, LIU X, LI J, et al. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy[J]. Theranostics,2021,11(9): 4171-4186.
WEN J, LIU F, TAO B, et al. GSH-responsive anti-mitotic cell penetrating peptide-linked podophyllotoxin conjugate for improving water solubility and targeted synergistic drug delivery[J]. Bioorg Med Chem Lett, 2019,29(8):1019-1022.
周菲,吴高荣,郭文博,等. 新型鬼臼毒素衍生物的合成及抗肿瘤活性研究[J].北京中医药大学中药学院,2020,35(1):100-105.
JOSÉ C J M D S, MENEZES, DIEDERICH M F. Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology[J]. Eur J Med Chem,2019, doi: 10.1016/j.ejmech.2019.111637http://dx.doi.org/10.1016/j.ejmech.2019.111637.
TAN J. Synthesis of chalcone derivatives and anti-breast cancer screening[J]. Chin J Mod Appl Pharm, 2016,33(3):318-325.
SINGH P, ANAND A, KUMAR V. Recent developments in biological activities of chalcones: A mini review[J]. Eur J Med Chem, 2014, doi: 10.1016/j.ejmech.2014.08.033http://dx.doi.org/10.1016/j.ejmech.2014.08.033.
LUO Y, WU W, ZHA D, et al. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents[J]. Bioorg Med Chem Lett,2021,47(s16):128230.
ZHOU B, HUANG J, ZUO Y, et al. 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage[J].Eur J Pharmacol,2013,707(1/3):130-139.
KAHLOS K, SOINI Y, SÄILY M, et al. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma[J]. Int J Cancer,2001,95(3): 198-204.
GORRINI C, HARRIS I S, MAK T W. Modulation of oxidative stress as an anticancer strategy[J]. Nat Rev Drug Discovery,2013,12(12):931-947.
AI Y, ZHU B, REN C, et al. Discovery of new monocarbonyl ligustrazine- curcumin hybrids for intervention of drug-sensitive and drug-resistant lung cancer[J]. J Med Chem,2016,59(5):1747-1760.
0
Views
9
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution